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Summary
Background Since 1976, erythroleukemia has been included within the FAB classification system of acute myeloid leukemia (AML) which designates it as M6 AML This report describes the data of 54 patients with newly diagnosed M6 AML, consecutively seen in our hospital between May 1976 and May 1999
Patients and methods There were 40 males and 14 females Median age was 59 years Pancytopenia was the most common feature at diagnosis Twenty-six percent of cases presented with secondary AML Karyotype was successfully performed in 35 cases Eleven patients presented with normal karyotype, nine with simple karyotypic abnormalities, and fifteen with major karyotypic abnormalities Fifty of the fifty-four patients received one or two courses of induction chemotherapy combining anthracyclines with cytarabine according to different successive protocols One elderly patient only received low-dose cytarabine, and three patients died before any chemotherapy could be given
Results Complete remission (CR) was achieved in 29 cases (54%, 95% confidence interval (CI) 40%-67%) As postremission therapy, four patients could be allografted, and two underwent autologous transplantation All other treated patients received continuation chemotherapy Twenty-one patients have relapsed (72%) Median time to relapse was six months. Among those patients, only eight achieved a second CR (38%) The median disease-free survival (DFS) was eight months (95% CI 4-10 months) with a five-year survival rale of 17% Median overall survival (OS) was nine months (95% CI 5-12 months) with a five-year survival rate of 13% In univanate analysis, poor prognostic factors for DFS were secondary AML (P = 0 05) and initial platelet count < 50 x 109/1 (P = 0 02). Poor prognostic factors for OS were age > 60 years (P -0.005), secondary AML(P = 0 05), initial 'blastic' fever (P -0 0004), and initial haemoglobin level < 90 g/1 (P = 0.03). All factors, but haemoglobin level, remained significant in the multivanate analysis Although it was not statistically significant, there was a trent for a better prognosis of M6 patients presenting with normal karyotype as compared to those displaying chromosomal abnormality.
Introduction
Erythroleukemia is a myeloprohferative disorder characterized by malignant proliferation of erythroid and myeloid precursors The disease has a long descriptive history which has gone through different stages of evolution. Although initially described in 1912 [1] , the term of 'erythroleukemia' was first proposed by Di Guglielmo in 1917 [2] In the late 1950s and 1960s, Dameshek proposed the term 'Di Guglielmo's syndrome' to describe a myeloprohferative syndrome striking erythoblastic hyperplasia and a progressive increase of myeloblasts terminating in AML [3, 4] . After 1976, erythroleukemia was no longer considered as a chronic myeloprohferative disorder but rather as a form of AML and as such was included within the French-American-British (FAB) classification system of AML which designates it as AML-M6 [5] . Among the various types of acute myeloid leukemia (AML), erythroleukemia is regarded as a relatively rare disorder and considered to be a distinct entity with characteristic features such as complex chromosomal defects and poor prognosis [6] [7] [8] [9] . Because of the rarity of this disorder, few investigators have accumulated sufficient numbers of cases to obtain data correlating various clinical and laboratory features with survival
We therefore reviewed data from 54 patients with newly diagnosed M6 subtype AML, consecutively seen in our hospital over a 23-year period, in order to better assess characteristics and outcome of this disease
Patients and methods

Patient population
All cases of adult (> 15 years old) patients with AML of M6 subtype, diagnosed according to FAB criteria [5. 10] and referred to our center over a 23-year period, were included in this study This meant that all patients were required to have a bone marrow (BM) with an erythroid component of at least 50% and myeloid blasts comprising at least 30% Three patients with poor general status died before any chemotherapy could be given One elderly patient only received low-dose cytarabine by subcutaneous route The fifty other patients were treated according to ongoing first line intensive intercalating agent and cytosine arabinoside ± VP16 ± 6-mercaptopunne-contaimng chemotherapy protocols Once complete remission (CR) was achieved, patients received either no maintenance therapy, conventional maintenance therapy, additional courses of myelosuppressive consolidation, or autologous transplantation according to the protocol design in which they were included All protocols included one or two courses of intensive consolidation Patients received standard supportive care during the neutropenic period Approximately 1/3 of patients older than 60 years who achieved CR received maintenance using low-dose cytarabine after one course of intensive consolidation During this period of time, none of the therapeutic protocols differed according to patient karyotype Patients aged less than 45 years with an HLA-identical family donor were scheduled to receive allogeneic bone marrow transplantation (BMT) following standard conditioning regimen Four patients underwent allogeneic BMT, and two received autologous transplantation
Evaluation of therapy
Complete remission was defined according to the CALGB criteria as less than 5% blasts in bone marrow aspirates with evidence of maturation of all cell lines and restoration of the peripheral blood counts [13] Failures to achieve CR were classified according to Preisler [14] Disease-free survival (DFS) was measured from the time of CR to the time of relapse or death, and overall survival (OS) from the time of initial diagnosis to the time of death Haematologic relapse was diagnosed when more than 5% blasts were seen in bone marrow aspirates of non-erythroid cells. Fifty-four patients with newly diagnosed untreated M6 AML and who fulfilled those criteria were retrospectively reviewed These patients represented about 3% of all AML cases seen during this time period Fourteen patients (26%) presented with secondary AML Indeed. M6 AML complicated chemotherapy given for malignant diseases in three cases (breast cancer in one patient, and Hodgkin's disease in two patients), and followed chronic haematologic myeloproliferative disorders in three cases (thrombocytopema in two patients, and chronic myeloid leukemia in one case) Five patients had a prior history ofmyelodysplastic syndrome Three patients have been previously exposed to benzene [6. 8. 9, 12] , the patients with chromosomal changes were divided into those with simple karyotypic abnormality and those
Statistical analysis
Both groups were compared with regard to initial characteristics (past history of malignancy, toxic or radiation exposure, or myelodysplastic syndrome, organomegaly, fever, blood counts, percent blasts in bone marrow, age, karyotypic data, serum enzymes) using Yates corrected chi-square or two-tailed Fisher's exact test, when appropriate for discrete variables, and Mann Whitney non parametric test for continuous variables The same parameters were analyzed for potential prognostic significance for complete remission (CR) achievement, DFS and OS Quantitative variables were treated as dichotomous in the analysis Cutoff points used were the conventional value defining elderly AML for age, the approximate median value for haematological parameters, and the upper limit of normal value for serum parameters Complete remission rates were compared using Yate's corrected chi-square and 95% Cl on proportions of CR patients were calculated using the exact binomial formula Survival and DFS probabilities were calculated using the Kaplan and Meier product-limit estimate method and their 95% symmetrical Cl limit was calculated according to Greenwood's method Survival curves were compared using the logrank test For analysis of survival and DFS of chemotherapy-treated patients, patients undergoing allogeneic or autologous bone marrow transplantation while in first CR were censored at the time of transplantation Prognostic factors for CR were studied using stepwise multiple logistic regression, and prognostic factors for DFS and over-all survival were studied using stepwise Cox's proportional hazard model All variables that were statistically (two-tailed P < 0 05) predictive for CR achievement or survival and their interactions were proposed for entry in the stepwise multivanate model for prediction of the same endpoint Goodness of fit of the models was tested using the likelihood ratio statistics All computations were made using BMDP software (BMDP Statistical Software, Los Angeles, California)
Results
Initial characteristics of the patients
From May 1976 to May 1999, 54 adults (40 males and 14 females, sex ratio' 2.8), seen in our institution at diagnosis, presented with AML of M6 subtype. Characteristics of the patients at diagnosis are indicated in Table 1 /l (range 6-334 x 10 9 /l). The incidence of tumoral syndrome was 31%. None of the patients presented with central nervous system (CNS) involvement Karyotypes were normal in 11 patients (31%). Simple karyotypes (9 patients, 26%) showed recurrent translocations such as t(9;22)(q34;qll) (1 case), t(3;12)(pl3;q26) (1 case), or partial deletion on the long arm of chromosome 20 (2 cases) or on the short arm of chromosome 1 (1 case), numerical changes such as tnsomy 8 (1 case), tnsomy 13 (1 case), or monosomy 7 (2 cases) as sole change. In complex karyotypes (15 patients; 43%), clonal changes combined partial or total deletion of chromosome 7 (12 cases; 34%), partial or total deletion of chromosome 5 (11 cases, 31%), monosomy 17 (8 patients; 23%), and miscellaneous changes such as deletions (del(4q) in three cases and del(12p) in 2 cases), translocations or chromosomal gains. Twelve patients (80%) displayed unidentified chromosomal rearrangements (markers) which could not be explained by the use of painting techniques. There were no significant differences between primary and secondary AMLs in terms of chromosomal rearrangements
Treatment outcome
CR was achieved in 29 (54%, 95% CI 40%-67%) patients after 1 (24 patients) or 2 (5 patients) induction courses CR rates were 65% and 40%, respectively, for patients aged less or more than 60 years (Table 2) . Six patients died during the first induction course. Four patients died with relative drug resistance and two patients died during induction with severe marrow hypoplasia. Median follow-up for the entire cohort at the time of analysis was 138 months. Twenty-one patients (72%) had relapsed at the time of analysis, and seven were in continuing CR for one to more than one hundred twenty-eight months. Only eight (38%) relapsed patients achieved a second CR. The median time to relapse was 6 months with a range of < 1-28 months. Median DFS time for remitters was eight months (95% CI 4-10 months) with 17% of patients in continuing CR at five years Median OS of the entire cohort was nine months (95% CI: 5-12 months) with 13% of patients surviving five years from the time of diagnosis (Figure 1 ). Four patients underwent HLA-identical allogeneic bone marrow transplantation from a suitable familial donor while in first CR: two of these died from leukemic relapse, while the other two died from graft versus host disease. Two patients received autologous stem-cell transplantation in first CR: both patients died from toxicity.
Prognostic/actors
No individual characteristic of patients was significantly associated with CR rate. Factors predictive for a short DFS in the univanate analysis included secondary AML (p = 0 05), and initial platelet count <50 x 10 9 /l (P = 0.02) Factors predictive for short OS included agê 60 years {P = 0.005), secondary AML (P -0.05), initial 'blastic' fever (P = 0.0004), and initial haemoglobin <90 g/1 (P = 0.03). In a multivanate analysis taking into account potentially prognostic factors, no single factor remained significantly predictive for CR achievement. Secondary AML (P = 0 02, relative risk (RR). 0.16; CI (RR): 0.05-1.98) and thrombocytopenia (P = 0.0001; RR. 0.97, CI(RR): 0.95-1.00) remained the prognostic factors for DFS. Only age (P = 0.003; RR: 1.03, CI (RR). 1.00-105), secondary AML (P = 0.03, RR. 0 45; CI (RR). 0.22-109), and 'blastic' fever (P = 0.03; RR' 0 39; CI (RR). 0 19-124) remained significant for OS in the multivanate analysis. Regarding karyotypic data, there was a trend for a better survival in patients with normal karyotype (median OS 18 months) as compared to those with abnormal karyotypes (median OS 5 months) (Figure 2 ) Among patients with abnormal karyotypes, there were no significant differences between those with simple and those with complex abnormalities.
Discussion
Because of its rare occurrence, M6 AML has not been extensively studied [15] . In our experience, M6 subtype represented about 3% of all AML seen during this 23-year time period. This represented a bit less than that previously reported by others [9, 16] However, this could be an underestimation because of the retrospective character of the study reviewing only patients initially classified as M6 at diagnosis. M6 AML is distinctive in that it is defined by an oligoblastic proliferation of both erythroid and myeloid precursors, while most AMLs exhibit a uniform proliferation of single cell type The FAB M6 subtype, that we choose as the morphological standard to characterize our M6 cases, is defined by an excess of myeloblasts or proerythroblasts in the setting of dyserythropoiesis. However, the FAB criteria for M6 AML have been the subject of some controversy since they were put forth [17] [18] [19] Indeed, recent studies have shown identical data between FAB M6 AML and pure erythroid malignancies such as Di Gughelmo disease in terms of clinical and laboratory features, cytogenetic patterns, and poor survival data suggesting that the FAB classification scheme should be modified to include those malignancies.
Erythroleukemia is distinguished by several features. Our data were in general in concordance with previous studies reported in the literature [16, 20] These patients present with pancytopenia. Almost all patients showed at presentation varying degrees of leukopenia The peripheral blast count in most of our patients was low.
This review of cases collected over the past 23 years reveals a wide age range from 19-84 years, although most patients are over 50 years of age at time of diagnosis [16] . M6 is generally viewed as a disease of the elderly The disease was primarily one of the elderly, but a subset of younger patients also emerged in our cases, whose clinical outcome was significantly better than that of the elderly patients. In contrast to most previous reports [16, 20] , there was a strong male sex predilection Like the other AMLs, M6 has been reported to complicate exposure to radiation or toxic drugs. M6 more commonly complicates treatment with alkalating agents and benzene exposure than any other types of AML [21] [22] [23] . Twenty-six percent of our M6 patients had secondary AML This high percentage is in accordance with previous studies [20] and may indicate the necessity of investigating a detailed occupational history of M6 patients. Erythroleukemia tendency to transform to other types of AML late in its course has been previously reported [16] , but was not assessed in our series because of the retrospective character of the study. However, several cases displayed this transformation (data not shown).
Erythroleukemia is cytogenetically heterogeneous with high frequency of complex karyotypes [6, 8, 9, 24, 25] However, no specific cytogenetic abnormalities have been consistently identified in the relatively small series of M6 patients previously reported Most chromosomal abnormalities, described in M6 patients, have been reported in poor-risk AML. Loss of material from chromosomes 5, 7 and/or 17 was noted in 17 out of 35 cases studied. This points to the absence of specificity of -5/5q-, -7, or -17 abnormalities. Unfortunately, cytogenetic analysis was only performed successfully after 1980, yielding karyotypic data in only 35 cases. However, our results suggest that chromosomal findings might be a useful prognostic indicator of M6 AML There exist at least two cytogenetically distinct groups with different outcomes according to the presence or absence of cytogenetic abnormality. This confirms previously reported obvious differences in response to chemotherapy among the karyotypic groups [6, 8, 9, 12] . In contrast to a previous report [12] , we did not find any difference between de novo AML and secondary AML in terms of karyotypic data.
It has been suggested that M6 patients respond less well to chemotherapy than other AML patients [26] [27] [28] . This is confirmed by our retrospective study, but remains to be rigorously demonstrated in prospective studies using FAB criteria for patient selection and uniform treatment regimens. Previous retrospective studies have shown that survival was significantly better for patients treated with a regimen including daunorubicin alone or in combination with cytarabine, as compared with other therapeutic combinations [20, 28] . Too few patients received allogeneic or autologous transplantation to evaluate the effects of these approaches on survival We notice survival differences among certain subgroups. In contrast to a previous report [20] , in which the group was subdivided according to age, a marked difference in survival was noted between the young subset and the older subset Another difference in survival emerged according to whether M6 was diagnosed de novo, or following chemotherapy, toxic exposure, or a chronic haematologic disorder, that has also been recognized as prognostic value by most previous studies [20, 29] In this retrospective study, we therefore confirmed the clinical aspects and the overall outcome of M6 AML. We also point to certain factors of prognostic value that would ultimately lead to a better understanding of this form of AML. However, larger series are still warranted in order to clarify treatment effects, particularly those of intensified therapy used as continuation treatment after CR achievement. Only a large prospective multicenter study with well-defined diagnostic criteria could break up those drawbacks inherent to a retrospective analysis.
